Hdac1 10197 1 ap

IHC was performed using standard protocols with citrate buffer (pH 6.0) pretreatment. Briefly, formaldehyde-fixed and paraffin-embedded liver sections were incubated with primary antibodies at 4 °C overnight and then with horseradish peroxidase-conjugated secondary antibodies at 37°C for 30 min. The sections were finally incubated with diaminobenzidine and counterstained with hematoxylin for detection. The antibody against RACK1 (610178) was ordered from BD Bioscience. The antibodies against HDAC1 (10197-1-AP) and S100A9 (26992-1-AP) were acquired from Proteintech.

The following primary antibodies were used in this study: Myc monoclonal antibody (M4439, Sigma-Aldrich), β-actin (A5441, Sigma-Aldrich), Flag (F3165, Sigma-Aldrich), HDAC1 (10197-1-AP, Proteintech), TARDBP (190782-2-AP, Proteintech), Acetylated-Lysine antibody (9441, Cell Signaling), GFP (33-260, ThermoFisher Scientific), caspase-3 (♯9662, Cell Signaling Technology), PARP (♯9542, Cell Signaling Technology), LC3B (♯2775, 2Cell Signaling Technology), anti-rabbit peroxidase-conjugated secondary antibody (AP132P EMD Millipore) and anti-mouse peroxidase-conjugated secondary antibody (AP124P EMD Millipore); anti-rabbit, anti-mouse Alexa 488 (A-11001, Life Technologies) or 647-conjugated secondary antibody (A-21244, Life Technologies). All antibodies were used at the dilution recommended by the manufacturer’s instructions.
The following HDACis were used in this study: Sodium phenil butyrate (SML0309, Sigma-Aldrich), Trichostatin A (T8552, Sigma-Aldrich), Sodium butyrate (B5887, Sigma-Aldrich), Valproic acid sodium salt (P4543, Sigma-Aldrich).